Quarterly report pursuant to Section 13 or 15(d)

Revenue - Collaboration Agreement - The GSK Termination and Transfer Agreement (Details)

v3.23.3
Revenue - Collaboration Agreement - The GSK Termination and Transfer Agreement (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2023
GBP (£)
Jun. 30, 2023
GBP (£)
Sep. 30, 2023
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2023
GBP (£)
Apr. 06, 2023
USD ($)
Apr. 06, 2023
GBP (£)
Revenue              
Revenue recognized in the period       $ 59,375,000      
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements     $ 305,197,000 305,197,000      
GSK Termination and Transfer Agreement              
Revenue              
Upfront payment received | £   £ 7,500,000          
Milestone payment | £ £ 3,000,000            
Potential milestone payments to be received | £         £ 19,500,000    
Amount of transaction price of the agreement at inception           $ 37,335,000  
Upfront and milestone payment receivable | £             £ 30,000,000
Revenue recognized in the period     0 0      
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements     36,609,000 36,609,000      
IGNYTE              
Revenue              
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements     20,501,000 20,501,000      
LTFU              
Revenue              
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements     $ 16,108,000 $ 16,108,000